ReviewSchizophrenia research2020
A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis.
Review in Schizophrenia research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05398120 (Testing the Feasibility of a Skills Group for Adolescents and Young Adults at Clinical High-risk for Psychosis), which is not on this map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testing the Feasibility of a Skills Group for Adolescents and Young Adults at Clinical High-risk for Psychosis
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- The association between attachment insecurity and negative symptoms in clinical and non-clinical populations: A systematic review and meta-analysis.Psychology and psychotherapy · 2026Pooled it
- Social functioning and brain imaging in individuals at clinical high-risk for psychosis: A systematic review.Schizophrenia research · 2021Pooled it
- The effect of monetary versus point-based rewards on effort-cost decision making in individuals at clinical high risk for psychosis.Schizophrenia research · 2026Trial
- Family-focused therapy for individuals at high clinical risk for psychosis: A confirmatory efficacy trial.Early intervention in psychiatry · 2022Trial
- Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia.Schizophrenia bulletin · 2026Article
- Mobile Technology for Real-Life Assessment of Positive and Negative Symptoms as well as Stress Among Individuals With Early Psychosis: A Scoping Review.Early intervention in psychiatry · 2026Article
- Computerized assessments of emotional expression and emotional reactivity predict negative symptoms in individuals at clinical high-risk for psychosis.Psychological medicine · 2026Article
- Persistent Negative Symptoms: Characterization of an Unmet Need in a Learning Health System for First-Episode Psychosis.Schizophrenia bulletin · 2026Article
- Subjective Perceptions of Digital Phenotyping Measures of Negative Symptoms Among Individuals At Clinical High Risk for Psychosis and Their Relatives.Schizophrenia bulletin open · 2026Article
- Relationship between cognitive reserve (education), social cognition and negative symptoms.Schizophrenia research. Cognition · 2025Article
- Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- The Negative Symptom Inventory-Psychosis Risk (NSI-PR): Psychometric Validation of the Final 11-Item Version.Schizophrenia bulletin · 2025Article
- Digital phenotyping evidence for the reduced positivity offset as a mechanism underlying anhedonia among individuals at clinical high-risk for psychosis.Schizophrenia research · 2025Article
- Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.Schizophrenia (Heidelberg, Germany) · 2025Article
- Persons at risk for psychosis overestimate social functioning compared to persons with major depressive disorder and community controls.Journal of psychiatric research · 2025Article
- The efficacy and safety of dual-target rTMS over dorsolateral prefrontal cortex (DLPFC) and cerebellum in the treatment of negative symptoms in first-episode schizophrenia: Protocol for a multicenter, randomized, double-blind, sham-controlled study.Schizophrenia research. Cognition · 2025Article
- Baseline Social Functioning Is Associated with Increased Likelihood of Remission from a Clinical High Risk for Psychosis Syndrome.Schizophrenia bulletin open · 2025Article
- Longitudinal Trajectories of Premorbid Social and Academic Adjustment in Youth at Clinical High Risk for Psychosis: Implications for Conversion.Schizophrenia bulletin · 2024Article
- Understanding the Psychosis Spectrum Using a Hierarchical Model of Social Cognition.Schizophrenia bulletin · 2024Article
- The Complex Latent Structure of Attenuated Psychotic Symptoms: Hierarchical and Bifactor Models of SIPS Symptoms Replicated in Two Large Samples at Clinical High Risk for Psychosis.Schizophrenia bulletin · 2024Article
Corrections and comments
- Reprinted as
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Studies attempting to deconstruct the heterogeneity of schizophrenia and the attenuated psychosis syndrome consistently find that negative symptoms are a core dimension that is distinct from other aspects of the illness (e.g., positive and disorganized symptoms). Negative symptoms are also highly predictive of poor community-based functional outcomes, suggesting they are a critical treatment target. Unfortunately, pharmacological and psychosocial treatments for negative symptoms have demonstrated limited effectiveness. To address this critical unmet therapeutic need, the NIMH sponsored a consensus development conference to delineate research priorities for the field and stimulate treatment development. A primary conclusion of this meeting was that next-generation negative symptom rating scales should be developed to address methodological and conceptual limitations of existing instruments. Although second-generation rating scales were developed for adults with schizophrenia, progress in this area has lagged behind for youth at clinical-high risk (CHR) for developing psychosis (i.e. those meeting criteria for a prodromal syndrome). Given that negative symptoms are highly predictive of the transition to diagnosable psychotic illness, enhancing our ability to detect negative symptoms in CHR youth is paramount. The current paper discusses conceptual and methodological limitations inherent to existing scales that assess negative symptoms in CHR youth. The theoretical and clinical implications of these limitations are evaluated. It is concluded that new scales specifically designed to assess negative symptoms in CHR youth are needed to accurately chart mental illness trajectories and determine when, where, and how to intervene. Recent efforts to develop next-generation measures designed specifically for CHR youth to meet this urgent need in the field are discussed. These new approaches offer significant progress for addressing issues inherent to earlier scales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.